$FRTX News
Last published 2y ago
- 2y agoFRTXFresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15thGlobeNewswireNew record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce
- 2y agoFRTXFresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19thGlobeNewswireBOULDER, Colo., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today receipt of a notice from Nasdaq stating that the Company's common stock
- 2y agoFRTXFresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of StockholdersGlobeNewswireMeeting adjourned to December 27, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 26, 2023 Company
- 2y agoFRTXFresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of StockholdersGlobeNewswireMeeting adjourned to December 15, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 14, 2023 Company
- 2y agoFRTXFresh Tracks Therapeutics Announces Adjournment of Special Meeting of StockholdersGlobeNewswireMeeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on November 29, 2023
- 2y agoFRTXFresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireCash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by
- 3y agoFRTXFresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and DissolutionGlobeNewswireBOULDER, Colo., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX) today announced that, after conducting an extensive potential strategic alternatives
- 3y agoFRTXFresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireStrengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB
- 3y agoFRTXFresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from BotanixGlobeNewswireBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by
- 3y agoFRTXFresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireReported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value
- 3y agoFRTXFresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePositive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis
- 3y agoFRTXFresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02GlobeNewswireFRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives Plasma concentrations within the potential therapeutic dose range were consistent
- 3y agoFRTXFresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive OfficerGlobeNewswireBOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms
- 3y agoFRTXFresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational AutoimmunityGlobeNewswireBOULDER, Colo., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms
- 4y agoFRTXFresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023 Advancing the
- 4y agoFRTXFresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022GlobeNewswireBOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks Therapeutics" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing
- 4y agoBBIFRTXFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02GlobeNewswireFRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept.